Effect of Wild Type PTEN Gene on Proliferation and Invasion of Multiple Myeloma

Overview

Journal Int J Hematol

Specialty Hematology

Date 2010 Jun 29

PMID 20582577

Citations 8

Authors

Suyun Wang

Zhiyong Cheng

Xiaoyang Yang

Kai Deng

Yan Cao

Hao Chen

Ling Pan

Affiliations

Soon will be listed here.

Abstract

We explored the effect of the wild type PTEN gene on the proliferation, apoptosis and invasive ability of multiple myeloma (MM) cells from MM patients and RPMI 8226 cells (a human myeloma cell line), and the effect of the PTEN/focal adhesion kinase (FAK)/MMP signaling pathway on the invasion activity of RPMI 8226 cells. The proliferation of RPMI 8226 cells and purified myeloma cells from MM patients were markedly inhibited after these cells were transfected with recombinant adenovirus-PTEN vectors containing green fluorescent protein (Ad-PTEN-GFP). Maximum growth inhibition of RPMI 8226 cells and purified myeloma cells from MM patients by AD-PTEN-GFP was 42.01 and 24.75%, respectively. After transfection with PTEN-siRNA, the proliferation of RPMI 8226 cells was increased significantly compared with NS-siRNA transfected controls. The maximal survival rate was 141.55 +/- 8.34% in PTEN-siRNA transfected RPMI 8226 cells. Apoptosis of RPMI 8226 cells or purified myeloma cells from MM patients in the Ad-PTEN-GFP group was increased significantly when compared with that in the Ad-GFP (adenovirus vectors only expressing green fluorescent protein) group (p < 0.01). The cell cycle of RPMI 8226 cells was arrested at the G2/M phase. Furthermore, the number of cells that migrated through the matrigel and filter from the upper chamber to the lower chamber in the transwell assay in the Ad-GFP group was significantly larger than that in the Ad-PTEN-GFP group (52.65 +/- 7.39 vs. 23.50 +/- 6.12, p < 0.01). In the PTEN-siRNA group, the cell number (79.50 +/- 11.89) was significantly larger than that in the NS-siRNA group (47.17 +/- 7.76, p < 0.01). When RPMI 8226 cells were transfected with Ad-PTEN-GFP or NS-siRNA, the expression level of PTEN mRNA was up-regulated, and the expression levels of FAK, MMP-2 and MMP-9 mRNA were down-regulated significantly compared with that of the Ad-GFP group and the PTEN-siRNA group (p < 0.01, p < 0.05). The protein levels of FAK and p-FAK, MMP-2 and MMP-9 in RPMI 8226 cells which were transfected with Ad-PTEN-GFP decreased significantly, but increased significantly in PTEN-siRNA transfected RPMI 8226 cells (p < 0.01, p<0.05). These results indicated that wild type PTEN, which inhibited FAK, MMP-2, and MMP-9, could suppress the proliferation and invasion ability of multiple myeloma cells. Modulating the expression of PTEN may be a potential strategy for the treatment of multiple myeloma.

Citing Articles

Circular RNA Protein Tyrosine Kinase 2 Promotes Cell Proliferation, Migration and Suppresses Apoptosis Activating MicroRNA-638 Mediated MEK/ERK, WNT/β-Catenin Signaling Pathways in Multiple Myeloma.

Zhou F, Wang D, Zhou N, Chen H, Shi H, Peng R Front Oncol. 2021; 11:648189.

PMID: 34395238 PMC: 8355695. DOI: 10.3389/fonc.2021.648189.

Nuclear Heparanase Regulates Chromatin Remodeling, Gene Expression and PTEN Tumor Suppressor Function.

Amin R, Tripathi K, Sanderson R Cells. 2020; 9(9).

PMID: 32899927 PMC: 7564302. DOI: 10.3390/cells9092038.

PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?.

Bazzichetto C, Conciatori F, Pallocca M, Falcone I, Fanciulli M, Cognetti F Cancers (Basel). 2019; 11(4).

PMID: 30925702 PMC: 6520939. DOI: 10.3390/cancers11040435.

Gambogenic Acid Exerts Antitumor Activity in Hypoxic Multiple Myeloma Cells by Regulation of miR-21.

Liu P, Wu X, Dai L, Ge Z, Gao C, Zhang H J Cancer. 2017; 8(16):3278-3286.

PMID: 29158801 PMC: 5665045. DOI: 10.7150/jca.19290.

Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.

Mithraprabhu S, Khong T, Spencer A Cell Death Dis. 2014; 5:e1134.

PMID: 24651437 PMC: 3973216. DOI: 10.1038/cddis.2014.98.

References

Tang Y, Eng C . PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner. Cancer Res. 2006; 66(2):736-42. DOI: 10.1158/0008-5472.CAN-05-1557. View

Canel M, Secades P, Garzon-Arango M, Allonca E, Suarez C, Serrels A . Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression. Br J Cancer. 2008; 98(7):1274-84. PMC: 2359633. DOI: 10.1038/sj.bjc.6604286. View

Tamura M, Gu J, Takino T, Yamada K . Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res. 1999; 59(2):442-9. View

Ge N, Rudikoff S . Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. Oncogene. 2000; 19(36):4091-5. DOI: 10.1038/sj.onc.1203801. View

Fassas A, Spencer T, Sawyer J, Zangari M, Lee C, Anaissie E . Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002; 118(4):1041-7. DOI: 10.1046/j.1365-2141.2002.03757.x. View

Zhang Y, Thant A, Hiraiwa Y, Naito Y, Sein T, Sohara Y . A role for focal adhesion kinase in hyluronan-dependent MMP-2 secretion in a human small-cell lung carcinoma cell line, QG90. Biochem Biophys Res Commun. 2002; 290(3):1123-7. DOI: 10.1006/bbrc.2001.6321. View

Kelly T, Borset M, Abe E, Sanderson R . Matrix metalloproteinases in multiple myeloma. Leuk Lymphoma. 2000; 37(3-4):273-81. DOI: 10.3109/10428190009089428. View

Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero M, Blade J, Moro M . Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999; 93(3):1032-7. View

Schlaepfer D, Mitra S . Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev. 2004; 14(1):92-101. DOI: 10.1016/j.gde.2003.12.002. View

10.

Hu Y, Sun C, Huang J, Hong L, Zhang L, Chu Z . Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J (Engl). 2007; 120(19):1672-7. View

11.

Qiang Y, Walsh K, Yao L, Kedei N, Blumberg P, Rubin J . Wnts induce migration and invasion of myeloma plasma cells. Blood. 2005; 106(5):1786-93. PMC: 1895227. DOI: 10.1182/blood-2005-01-0049. View

12.

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275(5308):1943-7. DOI: 10.1126/science.275.5308.1943. View

13.

Kyle R, Rajkumar S . Multiple myeloma. Blood. 2008; 111(6):2962-72. PMC: 2265446. DOI: 10.1182/blood-2007-10-078022. View

14.

Kornberg L . Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Head Neck. 1998; 20(8):745-52. DOI: 10.1002/(sici)1097-0347(199812)20:8<745::aid-hed14>3.0.co;2-z. View

15.

Smith A, Wisloff F, Samson D . Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006; 132(4):410-51. DOI: 10.1111/j.1365-2141.2005.05867.x. View

16.

Oktay M, Oktay K, Hamele-Bena D, Buyuk A, Koss L . Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas. Hum Pathol. 2003; 34(3):240-5. DOI: 10.1053/hupa.2003.40. View

17.

Bao H, Jiang M, Zhu M, Sheng F, Ruan J, Ruan C . Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol. 2009; 90(2):177-185. DOI: 10.1007/s12185-009-0356-8. View

18.

Van Valckenborgh E, Croucher P, De Raeve H, Carron C, De Leenheer E, Blacher S . Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. Am J Pathol. 2004; 165(3):869-78. PMC: 1618595. DOI: 10.1016/S0002-9440(10)63349-4. View

19.

Schlaepfer D, Hauck C, Sieg D . Signaling through focal adhesion kinase. Prog Biophys Mol Biol. 1999; 71(3-4):435-78. DOI: 10.1016/s0079-6107(98)00052-2. View

20.

Chang H, Qi X, Claudio J, Zhuang L, Patterson B, Stewart A . Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res. 2005; 30(3):262-5. DOI: 10.1016/j.leukres.2005.07.008. View